SEAGEN INC. – FDA 483, May 13, 2025
An FDA inspection of SEAGEN INC. in Bothell, WA, a drug intermediate manufacturer, identified deficiencies in the training and qualification process for operators performing aseptic filling of PADCEV mAb intermediate. The firm's qualification procedures were found to be inadequate in both initial training and evaluating continued proficiency, including the use of commercial lots for final qualification and a lack of periodic re-qualification requirements. These issues indicate a potential risk to product quality and patient safety.
ID · 2c35d8cb-a857-4b8a-ad27-b43ba4571b46
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.